Gsk cnbc：GSK.L: GSK plc
GSK.L: GSK plc
GSKplcisaglobalbiopharmacompany.TheCompany'ssegmentsincludeCommercialOperationsandResearchandDevelopment.Itdevelopscancermedicinesfor ...。其他文章還包含有：「GSKplc」、「GSK-GB:GSKplc」、「GLAXO-IN」、「GLAXF:GSKplc」、「GS71-DE:GSKplc」、「GSKsuesPfizerclaimingRSVvaccinepatentinfringement」、「RSVvaccine」、「RSVvaccineuptakewillstartslowerthanshinglesshot」
查看更多 離開網站
GSK plc
https://www.cnbc.com
Get GSK plc (GSK:NYSE) real-time stock quotes, news, price and financial information from CNBC.
GSK-GB: GSK plc
https://www.cnbc.com
Get GSK plc (GSK-GB:London Stock Exchange) real-time stock quotes, news, price and financial information from CNBC.
GLAXO-IN
https://www.cnbc.com
Get GlaxoSmithKline Pharmaceuticals Ltd (GLAXO-IN:National Stock Exchange of India) real-time stock quotes, news, price and financial information from CNBC.
GLAXF: GSK plc
https://www.cnbc.com
Get GSK plc (GLAXF:OTCPK) real-time stock quotes, news, price and financial information from CNBC.
GS71-DE: GSK plc
https://www.cnbc.com
Get GSK plc (GS71-DE:XETRA) real-time stock quotes, news, price and financial information from CNBC.
GSK sues Pfizer claiming RSV vaccine patent infringement
https://www.cnbc.com
GlaxoSmithKline sued Pfizer in U.S. court, alleging patent infringement over GSK's respiratory syncytial virus vaccine.
RSV vaccine
https://www.cnbc.com
The Food and Drug Administration approved GSK's RSV vaccine for adults ages 60 and older. · The GlaxoSmithKline shot is now the world's first ...
RSV vaccine uptake will start slower than shingles shot
https://www.cnbc.com
GlaxoSmithKline CEO Emma Walmsley said she expects uptake for the company's newly approved RSV vaccine to start off slower than it did for ...